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Abstract
Bicomponent fibers of two semi-crystalline (co)polymers, poly(ε-caprolactone),
PCL and poly(oxyethylene-b-oxypropylene-b-oxyethylene), Lu were obtained
by electrospinning. Acetazolamide and timolol maleate were loaded in the
fibers in different concentrations (below and above the drug solubility limit in
polymer) in order to determine the effect of drug solubility in polymer, drug
state, drug loading and fiber composition on fiber morphology, drug distribu-
tion and release kinetics. The high loadings fibers (with drug in crystalline
form) showed higher burst and faster release than low drug content fibers,
indicating the release was more sustained when the drug was encapsulated
inside the fibers, in amorphous form. Moreover, timolol maleate was released
faster than acetazolamide, indicating that drug solubility in polymer influ-
ences the partition of drug between polymer and elution medium, while fiber
composition also controlled drug release. At low loadings, total release was
not achieved (cumulative release percentages smaller than 100 %), suggest-
ing that drug remained trapped in the fibers. The modeling of release data
implied a three stage release mechanism: a dissolution stage, a desorption
and subsequent diffusion through water filled pores, followed by polymer
degradation control.
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1. Introduction
Electrospinning is a versatile technique through which a variety of con-
structs can be obtained with application in biomedicine (medical prosthesis,
tissue scaffolds, wound dressings, drug delivery, cosmetics), textiles, electric-
ity and optics, sensors, filtration, catalysis, unconventional energy sources
and storage cells [1, 2]. In the field of drug delivery and tissue engineer-
ing, electrospun polymer fibers have gained increasing importance because
they present several advantages: relatively easy drug entrapment during
the electrospinning process, obtaining of high loadings if so desired, burst
control, stability and preservation of drug/growth factor activity, high sur-
face area (which enhances drug release) and specific morphology which can
be easily controlled during the electrospining process [3]. Multicomponent
fibers have attracted special attention because new properties can be ob-
tained through the combination of different materials. Synthetic polymers
with good processability and good mechanical properties can be mixed with
natural polymers producing an increase in cellular attachment and biocom-
patibility [4]. Multicomponent fibers can be obtained mainly by two tech-
niques [5]: direct electrospinning of polymers solution (in a single-needle
configuration, if a mixture of polymers is co-dissolved in the electrospin-
ning solution or a multi-needle configuration in which the polymer solutions
are separated in parallel or concentric syringes) and post-treatment of the
single-component electrospun fibers (which can include coating with other
inorganic-polymer layers [6, 7], grafting [8], crosslinking [9], chemical vapour
deposition [10], functionalization with other (bio)polymers [11]). In addi-
tion to the new physico-chemical properties that arise from using various
components, a variety of fiber structures can be obtained such as core-shell
fibers, micro/nanotubes, interpenetrating phase morphologies (matrix dis-
persed or co-continuous fibers) [12, 13], nanoscale morphologies (spheres,
rods, micelles, lamellae, vesicle tubules, and cylinders) [14] and multilay-
ered constructs (either with different composition or different fiber diameter)
[15, 16].
For drug delivery applications, several polymers (in terms of degradabil-
ity and crystallinity) have been studied as well as drug/growth factor loading
in crystalline or amorphous form in order to fulfill specific requirements of
drug-eluting fiber mats (usually, good mechanical properties and biocom-
patibility are required together with control of drug release and burst effect
in order to ensure physical integrity of the construct, long term delivery or
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immediate action at the targeted location). There are several factors that
can affect the drug release from electrospun fibers: fiber construct geometry
and thickness [17], fiber diameter and porosity [18], fiber composition [19],
fiber crystallinity [20], fiber swelling [21], drug loading [18, 21], drug state
[22, 23], drug molecular weight [19, 24], drug solubility in the release medium
[21], drug-polymer-electrospinning solvent interactions [25, 26]. The release
characteristics of the fiber mat are highly influenced by the state of the drug
and the structure of the polymer that forms the fiber. For example, the crys-
tallinity of the polymer controls the rate of drug release as semi-crystalline
polymers showed in general a higher extent of burst because of two reasons:
on one hand, the instantaneous release of the drug deposited at the fiber sur-
face, and on the other hand, the hindered release of the drug from the fiber
bulk due to limited water uptake in the semi-crsytalline regions [20]. The
drug state in the fibers is also an important factor since it was shown that a
drug that is incorporated in crystalline form will mainly be deposited outside
the fibers and trigger burst release, while drug in amorphous state will be
loaded inside the fibers and be released in a sustained manner [22, 23, 27].
Drug loading is another factor that can affect the drug release: higher load-
ings will produce faster release ([18, 21, 22]); on one hand, at high loadings,
there is more surface segregated drug that dissolves fast and on the other
hand, there is an increase in porosity during drug elution proportional to
the initial amount of drug [18]. Drug compatibility with polymer solution
was also shown to be an important factor in controlling release, as lipophilic
drugs should be incorporated in lipophilic polymers and hydrophilic drugs
in hydrophilic polymers in order to avoid drug deposition outside fibers and
subsequent burst [26]. Moreover, the interaction between drug and the poly-
mer can block the crystallization of the drug in the fibers, if so desired [28]
and can even determine sustained release of drugs in crystalline state because
of chemical interaction with the polymer [24].
In our study, bicomponent fibers were prepared using poly(ε-caprolactone),
a semi-crystalline, more hydrophobic polymer and Lutrol F127 (poly(oxyethylene-
b-oxypropylene-b-oxyethylene)), also semi-crystalline, hydrophilic block copoly-
mer. Poly(ε-caprolactone) was selected because it has been used in a vari-
ety of electrospun fibers applications [3], while Lutrol F127 was added as
hydrophilicity enhancer and release modulator [29]. The properties of the
bicomponent fibers were studied in order to determine the effect of process-
ing on crystallinity, water contact angle and mass loss. As both polymers
are semi-crystalline, we could test the influence of such organization on the
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loading and release of drugs. Two drugs were selected for incorporation in
the fibers in different concentrations (below and above the drug solubility
limit in polymers), acetazolamide, a hydrophobic drug and timolol maleate,
a hydrophilic drug in order to determine the effect of drug solubility in poly-
mer, drug state, drug loading and fiber composition on fiber morphology,
drug distribution and release kinetics. Moreover, modeling of the release
data using a semi-empirical model (power law [30]) and a mechanistic model
(desorption model [31]) was performed, determining the release mechanism,
while the models were compared in terms of goodness of fit.
2. Materials and methods
2.1. Materials
Timolol maleate, (lot no. 90191189, 99,6 % purity) was purchased from
Cambrex Profarmaco Cork Ltd., while acetazolamide was obtained from
Sigma-Aldrich. Poly(ε-caprolactone) pellets (PCL, averageMw 65000 g/mol)
were obtained from Sigma-Aldrich. Lutrol F127 (Lu, 9000-14000 g/mol,
70 % by weight of polyoxyethylene) was bought from BASF. Acetone and
methanol, both spectrophotometric grade were obtained from Sigma-Aldrich.
Phosphate buffer saline (PBS) tablets (pH 7.4, 10 mM phosphate, 137 mM
sodium, 2.7 mM potassium), used to prepare the release medium were bought
from Sigma-Aldrich. All products were used without further purification.
2.2. Methods
2.2.1. Electrospinning
Lutrol F127 and PCL mixtures (25/75, 50/50, w/w) or PCL alone were
dissolved in acetone/methanol (4/1, v/v) at 15 % (w/v) and at 40 ◦C. The
final volume of each polymer solution was 3 ml. Acetazolamide and timo-
lol maleate were co-dissolved with the polymers (1 %, w/w). The electro-
spinning set-up consisted of a high voltage power supply (SL 10W-300W,
Spellman), delivery system (syringe, teflon tubing, 30 gauge needle, syringe
pump (NE-1000 Multiphaser, New Era Pump Systems)) and a rectangular
copper collector. A voltage of 20 kV was applied, while the syringe pump
was operated at a flow rate of 10 ml/min. Polymeric fibers were deposited on
aluminium paper covering the collector placed at a distance of 8 cm from the
needle tip. All electrospinning experiments were carried out under ambient
conditions (25 ◦C, 50 % humidity in average). The films deposited on the
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aluminium paper were peeled off and cut in rectangular pieces of 1 cm×1
cm. They were used as such in drug release experiments.
2.2.2. Morphological analysis and drug mapping
The morphology of the electrospun fiber and drug distribution were ex-
amined using scanning electron microscopy (SEM, Jeol JSM 5310) coupled
to an X-ray energy dispersion unit to determine the presence of elemental
sulphur (present in both drugs). The drug mapping for some of the samples
was done using electron probe microanalysis (Camebax SX50, Cameca) at 15
kV accelerated voltage and 40 nA probe current. SEM images were analyzed
using an image analysis software (ImageJ 1.42 [32]) and the average fiber di-
ameter was calculated by measuring the diameter of 40 fibers, selected from
different areas of the samples.
2.2.3. Fiber mat crystallinity, drug solubilitity in polymer and drug state
Films containing different drug percentages were prepared by solvent cast-
ing. Differential scanning calorimetry was carried out on a DSC Q100 equip-
ment (TA Instruments). Samples with masses of approximately 4 mg were
heated until 350 ◦C, at a heating rate of 10 ◦C/min in a hermetic pan, un-
der nitrogen atmosphere (100 mL/min). Drug concentration in the film was
plotted against drug melting enthalpy (calculated using Universal Analysis
2000 software (TA Instruments)) and the drug solubility in the polymer (as
percentage) was determined as the intercept of the linear regression curve.
The relative crystallinity of the fibers was calculated using Eq. 1.
Xrel (%) =
∆Hf
xLu∆Hf,100%Lu + xPCL∆Hf,100%PCL
× 100 (1)
where ∆Hf is the melting enthalpy determined in analysis by integrating the
peaks corresponding to polymer/blend melting, xLu and xPCL are Lu and
PCL mass fractions in the blend, while ∆Hf,100%Lu=181 J/g is the melting
enthalpy of 100 % crystalline Lu and ∆Hf,100%PCL=142 J/g is the melting
enthalpy of 100 % crystalline PCL [33]. The melting enthalpy of 100 %
crystalline Lu was calculated using Eq. 2.
∆Hf,100%Lu = xPPO∆Hf,100%PPO + xPEO∆Hf,100%PEO (2)
where xPPO and xPEO are polypropyleneoxide and polyethyleneoxide mass
fractions in Lutrol and ∆Hf,100%PPO and ∆Hf,100%PEO are the corresponding
melting enthalpies of 100 % crystalline polymer [34].
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2.2.4. Swelling and mass loss
Fiber films were accurately weighed and immersed in 4 ml phosphate
saline buffer (PBS) in sealed vials at 37 ◦C. At scheduled time intervals,
samples were withdrawn from the vials, blotted with a tissue paper to remove
the surface water and weighed. The water content (∆w) was calculated using
the Eq. 3.
∆w(%) =
mt −mi
mt
× 100 (3)
where mt denotes the mass of the wet sample at immersion time t and mi
denotes the initial mass of the sample.
For mass loss determination, at scheduled time intervals, samples were
withdrawn from the vials and vacuum dried until constant weight at 37 ◦C.
The percentage of mass loss (∆m) was calculated using Eq. 4.
∆m(%) =
mi −md
mi
× 100 (4)
where mi denotes the initial mass and md is the mass of the dried sample
after a certain immersion time.
2.2.5. Drug loading and release
The drug release from the fibers was studied in PBS medium (4 ml), us-
ing a shaker (37 ◦C, 100 rpm). At scheduled time intervals (1, 2, 3, 4, 7,
8, 9, 10, 11, 15, 19, 36, 52 days), 2 ml of sample was taken and fresh PBS
medium of identical volume was added to maintain sink conditions. The
mass of timolol maleate and acetazolamide released at time t, mt, as well as
the total drug amount (mtot) were determined by UV spectroscopy (Jasco
V-650 Spectrophotometer) at 299.5 nm and 265 nm, in PBS and 4/1 (v/v)
THF/methanol solution, respectively. The drug loading was determined us-
ing Eq. 5. The percentage of released drug was calculated using Eq. 6.
Calculations of the amount of released drug took into account replacement
with fresh medium at each sampling point. Controls (fibers without drug)
were also tested and their contribution to the absorbance was substracted.
Loading (%) =
mtot
mfiber
× 100 (5)
in which mfiber is the mass of the fiber mat.
Released drug (%) =
mt
mtot
× 100 (6)
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In order to study the drug release mechanism, different equations (Eq.7,
8) were used to model the release data. The equations were fitted to the
data using non-linear regression and the results were compared in terms of
goodness of the fit. The power law equation (Eq.7) is one of them and was
chosen because it is the most widely used equation in works concerning drug
release [30]:
mt
mtot
= a0 + k t
n (7)
where mt/mtot is the fractional release of the drug at time t, a0 is a constant,
representing the percentage of burst release, k is the kinetic constant and n
is the release exponent, indicating the mechanism of drug release.
In most models, the release mechanism has been attributed to diffusion
of the drug from the polymers and under this assumption, a 100 % release
of the drug is expected in a certain time. In the desorption model, the
authors suggest that release is not controlled by solid-state diffusion, but by
the desorption of the drug from pores of the fibers or from the outer surface
of the fibers. Thus, only the drug on the fiber and pore surfaces can be
released, whereas the drug from the bulk can not be released within the time
scales characteristic of the release experiments. The Eq.8 is based on a pore
model, in which the effective drug diffusion coefficient, Deff is considered and
not the actual diffusion coefficient in water, D (with Deff/D ≪ 1) because
desorption from the pore is the rate limiting step and not drug diffusion in
water, which is relatively fast.
mt
mtot
= α
[
1− exp
(
−
π2
8
t
τr
)]
(8)
where the porosity factor α = ms0/(ms0+mb0) < 1, with ms0 and mb0 being
the initial amount of drug at the fiber surface and the initial amount of drug
in the fiber bulk, respectively; mt is the drug amount released at time t,
while the total initial amount of drug in the fiber is mtot = ms0+mb0 and τr
is the characteristic time of the release process[31].
2.2.6. Statistics
All values are presented as mean (n=3) and standard error of the mean
(SEM). Linear regression analysis was performed using OpenOffice.org Calc
3.1 [35], while non-linear regression was done using the regression module
of SigmaPlot 10 [36]. Adjusted R2 (AdjR2) was calculated instead of R2 to
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Sample Drug solubility (%) Rel. degree of crystallinity (%)
Timolol maleate Acetazolamide Timolol maleate Acetazolamide
PCL 4.48 (1.11) 16.53 (2.1) 54.39 54.59
25/75 Lu/PCL 5.14 (0.94) 15.94 (4.81) 54.71 59.55
50/50 Lu/PCL 6.97 (1.86) 14.81 (0.8) 64.01 59.89
Lu 8.34 (1.54) 11.25 (3.92)
Table 1: Drug solubility in polymer
evaluate goodness of fit for the two equations that have different number of
model parameters.
3. Results and discussion
3.1. Fiber mat crystallinity, drug solubilitity in polymer and drug state
In this work, two drugs, timolol maleate (pka= 3.9, experimental logP=
1.2, experimental water solubility= 2.74 mg/ml [37]) and acetazolamide (pka=7.2,
experimental LogP= -0.26, experimental water solubility= 0.98 mg/ml [38])
with the chemical structures shown in Fig. 1 were chosen because of different
hydrophilic/hydrophobic character that would allow us to understand how
the interactions between the drug and polymers contribute to drug release.
Thus, as a measure of interaction, the drug solubility in polymers was de-
termined and the obtained results are presented in Table 1. Moreover, the
drug solubility is expected to influence the loading and the state of the drug
in the fibers. Thus, fibers with low and high drug loadings (see Table 4)
were prepared corresponding to drug percentages below and above the drug
solubility limit, respectively.
It was observed that acetazolamide had higher solubility in all fibers when
compared to timolol maleate probably because of enhanced interaction with
the hydroxyl/carboxyl groups of the polymers (the chemical structures are
shown in Fig.1). Furthermore, a tendency of increase in solubility was noticed
when PCL ratio is increased. On the other hand, timolol is more hydrophilic,
therefore a higher solubility is expected in the fibers that contain more Lu and
are more hydrophilic, which is the case of 50/50 Lu/PCL [29]. An opposite
trend was observed for timolol maleate when an increase in solubility was
obtained with decrease in PCL content. We will discuss in section 3.4 how
the solubility affects the drug release.
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Figure 1: Chemical structures
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Polymer crystallinity is known to play an important role in determining
degradability, water and drug release because the bulk crystalline phases
are more inaccessible to water. The polymers used in this work are semi-
crystalline and the obtained fibers are expected to be semi-crystalline too.
DSC analysis confirmed this hypothesis showing a clear melting peak in all
fibers (PCL melts at 65.1 ◦C and Lu melts at 59.4 ◦C). The relative degree
of crystallinity of drug loaded fibers is presented in Table 1, where it can be
seen that the fibers showed similar crystallinity values regardless the type of
loaded drug. Another important fact was that the drug appeared to be in
amorphous state in fibers with low drug loadings as proven by the absence of
drug melting peak in Fig. 2 (acetazolamide melts at 271.0 ◦C, while timolol
maleate melts at 205.6 ◦C). In fibers with high loadings, part of the drug
was in crystalline form as confirmed by morphological analysis (in the DSC
scans of these sample (Fig. 3), there is a broad peak possibly corresponding
to drug melting, that is unfortunately masked by fiber degradation process
that starts at around 250 ◦C).
3.2. Morphological analysis and drug mapping
The morphology of the fibers with low drug loadings as function of com-
position is presented in Fig. 4, while the calculated fiber diameters are shown
in Table 2. There was a slight variation in fiber diameter as a function of
loaded drug and a more significant one with respect to fiber composition.
Morphological differences between samples loaded with the two drugs above
or below the solubility limit were also assesed by SEM analysis. In Fig.5(a)
and Fig. 5(c) surface and cross-section images of fibers that contain aceta-
zolamide above solubility limit are shown. As the loaded mass of drug was
above the solubility limit in the polymer, the drug was expected to be in
crystalline form as confirmed by the images where drug crystals were visible
outside or inside the fibers. On the other hand, no crystals were observed in
the fibers that contain drug in low loadings (Fig.4) suggesting that the drug
was in amorphous state in the fibers in agreement with DSC analysis results.
SEM coupled with elemental analysis was performed in order to assess
the drug distribution inside the fiber mats. It was seen that both surface and
cross-section showed relatively homogeneous drug distribution regardless of
composition or type of loaded drug (Fig. 5(b) to Fig. 6(d)).
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(a)
(b)
Figure 2: DSC curves of fiber mats. a) low timolol loading; b) low acetazolamide loading
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Figure 3: DSC curves of fiber mats with high acetazolamide loading versus pure drug
sample drug d (µm)
PCL timolol 1.59 (0.36)
PCL acetazolamide 0.71 (0.45)
25/75 Lu/PCL timolol 1.01 (0.20)
25/75 Lu/PCL acetazolamide 0.87 (0.45)
50/50 Lu/PCL timolol 0.56 (0.11)
50/50 Lu/PCL acetazolamide 0.55 (0.12)
Table 2: Fiber diameters
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(a)
(b)
(c)
Figure 4: SEM images of fibers with low drug loadings. a) PCL with timolol; b) 50/50
Lu/PCL with timolol; c) 25/75 Lu/PCL with acetazolamide
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(a) (b)
(c) (d)
Figure 5: SEM of high acetazolamide content 25/75 Lu/PCL fibers and sulphur mapping.
a) Surface view; b) Surface mapping; c) Cross-section view; d) Cross-section mapping
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(a) (b)
(c) (d)
Figure 6: SEM of high timolol content fibers and sulphur mapping. a) PCL, surface view;
b) 25/75 Lu/PCL, surface view; c) PCL, surface mapping; d) 25/75 Lu/PCL, surface
mapping
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sample contact angle
PCL 123.18 (0.98)
25/75 Lu/PCL 18.28 (4.07)
50/50 Lu/PCL 16.25 (2.16)
Table 3: Static contact angle with water
3.3. Swelling and mass loss
The fiber mats are supposed to function in an aqueous environment, so
their properties in the presence of water have to be known. In Table 3, the
values of the water contact angles are given for the different fibers. PCL
fibers were highly hydrophobic, while the bicomponent fibers were highly
hydrophilic. These results were surprising since in a previous work films with
the same compositions presented contact angles in the range 50-62 degrees
[29]. Water contact angle is determined by both chemical structure and
surface morphology. In general, fiber mats have a rougher surface morphology
when compared to films and as a result they present higher contact angle
than the films made of the same polymers [39]. It seems this is the case
of PCL that showed an increase in water contact angle from 62 for films
to 123 for fibers. In contrast, the bicomponent fibers presented much lower
contact angles probably because of a preferential arrangement of Lu (that is
very hydrophilic) towards the margin of the fibers. Lu has a lower molecular
weight than PCL and higher molecular mobility and consequently it migrates
to the regions of highest shear rate (at the walls of the needle). The higher
viscosity component (PCL) occupies mostly the center of the fiber [40].
Consequently, PCL fibers absorbed water gradually (see Fig. 7(a)) be-
cause the fibers were hydrophobic and semi-crystalline, hindering the water
penetration inside the fiber mat, while the bicomponent fibers presented
a sudden increase in water content during the first day (79.0 % for 50/50
Lu/PCL and 68.5 % for 25/75 Lu/PCL), followed by a constant value there-
after as Lu content in the fiber was diminished due to dissolution.
As observed in the mass loss plot (Fig.7(b)), there was an initial increase
in mass loss for bicomponent fibers (42.5 % for 50/50 Lu/PCL and 16.6 %
for 25/75 Lu/PCL), while PCL fibers did not show almost any mass loss
(0.45 %). Mass loss of PCL is detectable only after the molecular weight
reaches a value of 10000 g/mol [41] and thus the initial high mass loss of the
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bicomponent fibers can only be attributed to the dissolution of Lu as the
sample with higher Lu content had the highest mass loss.
The morphology of aged fibers (immersed in PBS during 3 days) was also
investigated in order to determine the change in fiber structure. In Fig.8(a),
it can be noticed the smooth surface of the fibers, while in Fig.8(b) pores
were observed that were formed due to the dissolution and leaching of Lu.
A different appearance was shown by 25/75 Lu/PCL fiber mat (Fig.8(d)),
where the fibers appeared more wrinkled in comparison with the initial ones
and no pores were visible, probably because of lower Lu content.
3.4. Drug release
We previously showed how the fiber morphology and drug deposition were
affected by the drug state in the fibers: when drug was in amorphous state,
it was incorporated inside the fibers, while the drug present in amounts
above the solubility limit crystallized inside and on the fiber surface (as
shown in Fig. 5(a)). In Fig. 9(a) and Fig. 9(b), the cumulative percentage
of released acetazolamide and timolol maleate from fibers with low drug
content is presented, while in Fig. 10(a), the released drug for fibers with high
loadings is shown. It was noticed that fibers with high drug loading presented
burst release in contrast with low drug content fibers that showed a more
sustained release. The former contained drug crystals at the fiber surface or
inside the fibers that were not totally encapsulated and were instantaneously
“released”, implying that the predominant mechanism of release was drug
dissolution. On the other hand, in the low loadings fibers, the drug was
amorphous and dissolved in the fiber, decreasing burst. These findings were
in agreement with another study where bicomponent fibers loaded with 25%
drug (by weight) showed burst release as opposed to 5% drug fibers [20] that
did not, suggesting that the drug state can control the burst extent.
In Table 4, the results of non-linear regression are presented. The objec-
tive behind fitting these equations to the release data was to understand the
underlying phenomena involved in the drug release mechanism. The param-
eters a0, α and k define the burst stage and the bigger values they have, the
higher extent of burst. On the other hand, τ and n indicate the magnitude
of the drug desorption/diffusion stage and the higher values they have, more
sustained is the release.
Drug solubility in polymer as well as drug solubility in solution are im-
portant as they control the partitioning of the drug from the polymer toward
17
(a)
(b)
Figure 7: Water uptake and mass loss, (•) PCL, (◦) 25/75 Lu/PCL, (H) 50/50 Lu/PCL
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(a) (b)
(c) (d)
Figure 8: SEM images of a) initial 50/50 Lu/PCL, b) 50/50 Lu/PCL aged, c) initial 25/75
Lu/PCL, d) 25/75 Lu/PCL aged
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(a)
(b)
Figure 9: Drug release a) low loadings fibers with acetazolamide, b) low loadings fibers
with timolol maleate (solid and dashed lines corresponding to non-linear fit of Eq.8)
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(a)
Figure 10: Drug release of high loadings fibers
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Sample Loading
(%,
w/w)
Desorption model Power law
α τ (days) Adj R2 a0 k
(day−n)
n Adj R2
PCL,
timolol
0.88
(0.01)
45.96
(2.92)
7.94
(0.03)
0.86 5.08
(3.63)
11.51
(3.23)
0.37
(0.06)
0.92
25/75
Lu/PCL,
timolol
0.86
(0.02)
50.41
(2.95)
0.87
(0.76)
0.00 26.93
(2.71)
12.58
(2.72)
0.26
(0.05)
0.90
50/50
Lu/PCL,
timolol
0.88
(0.04)
64.60
(2.99)
1.10
(0.40)
0.33 26.34
(3.74)
25.97
(4.09)
0.15
(0.03)
0.90
PCL,
timolol
7.60
(0.32)
87.29
(0.46)
0.02
(6.51)
0.55
25/75
Lu/PCL,
timolol
6.99
(0.19)
98.55
(0.27)
0.01
(8.66)
0.40
PCL,
acetazo-
lamide
1.24
(0.28)
35.14
(1.43)
4.11
(0.05)
0.92 0.00
(4.76)
17.09
(4.88)
0.24
(0.06)
0.82
25/75
Lu/PCL,
acetazo-
lamide
1.55
(0.60)
40.59
(0.62)
0.37
(1.48)
0.96 1.16
(1.66)
36.60
(1.92)
0.03
(0.01)
0.98
50/50
Lu/PCL,
acetazo-
lamide
1.16
(0.20)
30.50
(1.16)
0.91
(0.46)
0.54 10.99
(1.06)
14.49
(1.18)
0.12
(0.02)
0.96
25/75
Lu/PCL,
acetazo-
lamide
12.67
(0.35)
98.08
(0.24)
0.05
(0.59)
0.99
Table 4: Drug loading and model parameters determined by non-linear regression
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the elution medium. For the same type of fibers, higher percentages of tim-
olol maleate were released in comparison with acetazolamide (for example,
in the case of PCL fibers, α=45.96 (2.92) for timolol and α=35.14 (1.43)
for acetazolamide). This can be explained by the combined effect of lower
polymer solubility and higher water solubility of timolol maleate in contrast
with acetazolamide that has higher polymer solubility and lower water sol-
ubility. The compatibility between drug and polymer is indeed important
as it ensures sustained release during drug diffusion from the polymer [26],
when the drug is completely encapsulated and dissolved in the fiber.
Fiber composition influenced the release kinetics as drug was released
in a more sustained manner from PCL fibers (α=45.96 (2.92) and k=11.51
(3.23) for timolol) than from bicomponent fibers regardless of the drug type
(α=50.41 (2.95) and k=12.58 (2.72) for 25/75 Lu/PCL with timolol, while
α=64.60 (2.99) and k=25.97 (4.09) for 50/70 Lu/PCL with timolol). Cer-
tainly, as erosion was very fast (see section 3.3), the drug was released faster
from bicomponent fibers than from the hydrophobic PCL fibers that released
the drug at the pace dictated by water uptake.
It was observed that a steady state was attained (after approximately 10
days for bicomponent fibers and after 20 days for PCL fibers) without total
release of loaded drug (cumulative release percentages significantly smaller
than 100 %). There is a fraction of the drug that is desorbed from the fiber
and then diffuses out through the water filled pores, while another portion
of the drug encapsulated probably in crystalline areas (and inaccessible to
water) can only be released by polymer degradation (which is insignificant
during the time scale of release experiment) [31, 42]. This was not the case
for the high drug loading fibers where release was almost complete in the
time frame of the experiment. At high loadings, when a significant amount
of drug was in crystalline form, only a small portion of drug was trapped
(approximately 10 % in the case of PCL, see Fig. 10(a)). As drug was in
crystalline state (with crystal dimensions between 1 to 6 µm), additional
regions of macroporosity were created after drug dissolution besides those
created by water uptake and polymer erosion, increasing surface area and
enhancing drug release. Thus, the state of the drug in the fiber has an
important part in further controlling release kinetics.
The release kinetics and regression analysis results implied a three stage
release mechanism, with different stages depending on fiber composition: the
first stage was drug dissolution (mainly because of crystalline drug that is
not totally encapsulated in the fibers), the second was drug desorption and
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subsequent diffusion through water-filled pores [43] (created either due to Lu
leaching or water uptake in the amorphous regions of PCL), while the last
stage was controlled by polymer degradation.
4. Conclusions
Fibers were obtained by electrospinning of two semi-crystalline (co)polymers,
PCL and Lu, and were loaded with two drugs, acetazolamide and timolol
maleate, in concentrations below and above the drug solubility limit in poly-
mer. The PCL fibers were semi-crystalline and hydrophobic, while the bicom-
ponent fibers were semi-crystalline and hydrophilic. Thus, the bicomponent
fibers showed high water uptake and extensive erosion during the first day,
whereas PCL fibers swelled gradually, without any significant erosion during
the time frame of the release experiment. Morphological examination showed
that fibers with high drug loadings (above solubility limit) had drug crystals
inside and outside the fibers, while fibers with low drug content (below sol-
ubility limit) had drug encapsulated in amorphous form. These results were
further supported by DSC analysis, where thermograms of low drug loading
fibers didn’t show the peak corresponding to drug melting.
The high loadings fibers showed higher extent of burst and shorter pe-
riods of release (almost 90 % of drug released after 2 days) than low drug
content fibers (around 50 % of drug released after 52 days), suggesting that
loading and drug encapsulation in either crystalline or amorphous form are
interelated and control the release rate, especially in the burst stage. Thus,
in long term release applications where high amounts of loaded drug are de-
sirable, a compromise must be found in order to balance the loading and
release rate that seem to vary in opposite directions according to the present
study.
Total release was not attained at low loadings, suggesting that the last
stage of the release kinetics was polymer degradation limited. Moreover, it
was observed that timolol maleate was released faster than acetazolamide in
the same type of fibers and similar loadings, indicating that drug solubil-
ity in polymer influenced the partition of drug between polymer and elution
medium. This could offer a mean to control the total percentage of released
drug by choosing the best pair of polymer and drug, although some applica-
tions require very specific material properties that may not match in terms
of compatibility the drugs used in the treatment of the targeted diseases.
Finally, the modelling of release data implied a three stage release mecha-
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nism: a dissolution stage (mainly produced by crystalline drug that was not
properly encapsulated), a drug desorption coupled to diffusion stage, followed
by polymer degradation control stage. The fiber composition also controled
drug release, since release was slower from PCL fibers than from bicompo-
nent fibers regardless of the drug type. By choosing the polymers making up
the bicomponent fibers and their ratio, the magnitude of the dissolution or
diffusion stage can be controlled, attaining the targeted short or long term
release application, respectively.
5. Acknowledgements
FCT (Fundac¸a˜o para a Cieˆncia e a Tecnologia) financial support is ac-
knowledged by Ma˘da˘lina V. Natu (SFRH/BD/30198/2006).
References
[1] M. T. Hunley, T. E. Long, Electrospinning functional nanoscale fibers:
a perspective for the future, Polym Int 57 (2008) 385-389
[2] Z.-M. Huang, Y.-Z. Zhang, M. Kotaki, S. Ramakrishna, A review
on polymer nanofibers by electrospinning and their applications in
nanocomposites, Composites Science and Technology 63 (2003) 2223-
2253
[3] S. Agarwal, J. H. Wendorff, A. Greiner, Use of electrospinning technique
for biomedical applications, Polymer 49 (2008) 5603-5621
[4] M J McClure, S A Sell, C E Ayres, D G Simpson, G L Bowlin (2009)
Electrospinning-aligned and random polydioxanone-polycaprolactone-
silk fibroin-blended scaffolds: geometry for a vascular matrix. Biomed
Mater, doi:10.1088/1748-6041/4/5/055010
[5] K M. Sawicka, P Gouma (2006) Electrospun composite nanofibers
for functional applications. Journal of Nanoparticle Research,
doi:10.1007/s11051-005-9026-9
[6] C L. Casper, W Yang, M C. Farach-Carson, J F. Rabolt (2007)
Coating Electrospun Collagen and Gelatin Fibers with Perlecan Do-
main I for Increased Growth Factor Binding. Biomacromolecules,
doi:10.1021/bm061003s
25
[7] J A Lee, K C Krogman, M Ma, R M Hill, P T Hammond, G C Rutledge
(2009) Highly Reactive Multilayer-Assembled TiO2 Coating on Electro-
spun Polymer Nanofibers. Adv Mater, doi:10.1002/adma.200802458
[8] Z Ma, M. Kotaki, S. Ramakrishna (2006) Surface modied nonwoven
polysulphone (PSU) ber mesh by electrospinning: A novel afnity mem-
brane. Journal of Membrane Science, doi:10.1016/j.memsci.2005.07.038
[9] S J Lee, J J Yoo, G J. Lim, A Atala, J Stitzel (2007) In vitro evaluation of
electrospun nanofiber scaffolds for vascular graft application. J Biomed
Mater Res A, doi:10.1002/jbm.a.31287
[10] J Zeng, A Aigner, F Czubayko, T Kissel, J H. Wendorff, A Greiner
(2005) Poly(vinyl alcohol) Nanofibers by Electrospinning as a Protein
Delivery System and the Retardation of Enzyme Release by Additional
Polymer Coatings. Biomacromolecules, doi:10.1021/bm0492576
[11] C L. Casper, N Yamaguchi, K L. Kiick, J F. Rabolt (2005) Function-
alizing Electrospun Fibers with Biologically Relevant Macromolecules.
Biomacromolecules, doi:10.1021/bm050007e
[12] M. Bogntizki, T. Frese, M. Steinhart, A. Greiner, J. H. Wendorff (2001)
Preparation of Fibers With Nanoscaled Morphologies: Electrospinning
of Polymer Blends. Polym Eng Sci, doi:10.1002/pen.10799
[13] M. Wei, B. Kang, C. Sung, J. Mead (2006) Core-Sheath Structure in
Electrospun Nanofibers from Polymer Blends. Macromol Mater Eng,
doi:10.1002/mame.200600284
[14] V Kalra, P A. Kakad, S Mendez, T Ivannikov, M Kamperman, Y
L Joo (2006) Self-Assembled Structures in Electrospun Poly(styrene-
block-isoprene) Fibers. Macromolecules, doi:10.1021/ma052643a
[15] C.M. Vaz, S. van Tuijl, C.V.C. Bouten, F.P.T. Baaijens (2005)
Design of scaffolds for blood vessel tissue engineering using
a multi-layering electrospinning technique. Acta Biomaterialia,
doi:10.1016/j.actbio.2005.06.006
[16] Q P Pham, U Sharma, A G Mikos (2006) Electrospun Poly(E-
caprolactone) Microfiber and Multilayer Nanofiber/Microfiber Scaffolds:
26
Characterization of Scaffolds and Measurement of Cellular Infiltration.
Biomacromolecules, doi:10.1021/bm060680j
[17] T Okuda, K Tominaga, S Kidoaki (2009) Time-programmed dual release
formulation by multilayered drug-loaded nanober meshes. Journal of
Controlled Release, doi:10.1016/j.jconrel.2009.12.029
[18] W Cui, X Li, X Zhu, G Yu, S Zhou, J Weng (2006) Investigation
of Drug Release and Matrix Degradation of Electrospun Poly(DL-
lactide) Fibers with Paracetanol Inoculation. Biomacromolecules,
doi:10.1021/bm060057z
[19] G Buschle-Diller, J Cooper, Z Xie, Y Wu, J Waldrup, X Ren (2007)
Release of antibiotics from electrospun bicomponent fibers. Cellulose,
doi: 10.1007/s10570-007-9183-3
[20] El-Refaie Kenawy , Gary L. Bowlin , Kevin Mansfield , John Layman ,
David G. Simpson, Elliot H. Sanders, Gary E. Wnek, Release of tetra-
cycline hydrochloride from electrospun poly(ethylene-co-vinylacetate),
poly(lactic acid), and a blend, Journal of Controlled Release 81 (2002)
57-64
[21] Z Xie, G Buschle-Diller (2009) Electrospun Poly(D,L-lactide) Fibers for
Drug Delivery: The Influence of Cosolvent and the Mechanism of Drug
Release. Journal of Applied Polymer Science, doi: 10.1002/app.31026
[22] M Zamani, M Morshed, J Varshosaz, M Jannesari (2010) Controlled
release of metronidazole benzoate from poly(ǫ-caprolactone) electrospun
nanobers for periodontal diseases. European Journal of Pharmaceutics
and Biopharmaceutics, doi:10.1016/j.ejpb.2010.02.002
[23] J Xie, C-H Wang (2006) Electrospun Micro- and Nanofibers for Sus-
tained Delivery of Paclitaxel to Treat C6 Glioma in Vitro. Pharmaceu-
tical Research, doi: 10.1007/s11095-006-9036-z
[24] P Taepaiboon, U Rungsardthong , P Supaphol (2006) Drug-loaded
electrospun mats of poly(vinyl alcohol) fibres and their release char-
acteristics of four model drugs. Nanotechnology, doi:10.1088/0957-
4484/17/9/041
27
[25] S Y Chew, J Wen, E K F Yim, K W Leong (2005) Sustained Release
of Proteins from Electrospun Biodegradable Fibers. Biomacromolecules,
doi: 10.1021/bm0501149
[26] J Zeng, L Yang, Q Liang, X Zhang, H Guan, X Xu, X Chen, X Jin
(2005) Influence of the drug compatibility with polymer solution on the
release kinetics of electrospun fiber formulation. Journal of Controlled
Release, doi:10.1016/j.jconrel.2005.02.024
[27] R.A. Thakur, C.A. Florek, J. Kohn, B.B. Michniak, Electrospun nanofi-
brous polymeric scaffold with targeted drug release profiles for potential
application as wound dressing, International Journal of Pharmaceutics
364 (2008) 87-93
[28] Deng-Guang Yu, Xia-Xia Shen, Chris Branford-White, Kenneth White,
Li-Min Zhu and S W Annie Bligh, Oral fast-dissolving drug delivery
membranes prepared from electrospun polyvinylpyrrolidone ultrafine
fibers, Nanotechnology 20 (2009), 1-9.
[29] M.V. Natu, M.H. Gil, H.C. de Sousa, Supercritical solvent im-
pregnation of poly(ε-caprolactone)/poly(oxyethylene-b-oxypropylene-
b-oxyethylene) and poly(εcaprolactone)/poly(ethylene-vinyl acetate)
blends for controlled release applications, J. Sup. Fluids 47 (2008) 93-
102.
[30] N.A. Peppas, L. Brannon-Peppas, Water Diffusion and Sorption in
Amorphous Macromolecular Systems and Foods, J Food Eng 22 (1994)
189-210.
[31] R. Srikar, A. L. Yarin, C. M. Megaridis, A. V. Bazilevsky, E. Kelley,
Desorption-Limited Mechanism of Release from Polymer Nanofibers,
Langmuir 2008, 24, 965-974
[32] ImageJ, Image processing and analysis in Java, http://rsbweb.nih.
gov/ij/, Accesed March 9, 2010.
[33] H. Tsuji, Y. Ikada, Blends of Aliphatic Polyesters. II. Hydrolysis of
Solution-Cast Blends from Poly( L-lactide ) and Poly(ε-caprolactone)
in Phosphate-Buffered Solution, J Appl Polym Sci 67 (1998) 405-415.
28
[34] ATHAS data bank, http://athas.prz.edu.pl/Default.aspx?op=db,
Accesed March 9, 2010.
[35] http://www.openoffice.org/, Accesed March 9, 2010.
[36] http://www.sigmaplot.com/products/sigmaplot/
sigmaplot-details.php, Accesed March 9, 2010.
[37] Drug card for timolol (DB00373), DrugBank database, http://www.
drugbank.ca/drugs/DB00373, Accesed March 9, 2010.
[38] Drug card for acetazolamide (DB00819), DrugBank database, http:
//www.drugbank.ca/drugs/DB00819, Accesed March 9, 2010.
[39] M. Kang, R. Jung, H.-S. Kim, H.-J. Jin, Preparation of superhydropho-
bic polystyrene membranes by electrospinning, Colloids and Surfaces A:
Physicochem. Eng. Aspects 313-314 (2008) 411-414.
[40] M. Wei, B. Kang, C. Sung, J. Mead, Core-Sheath Structure in Elec-
trospun Nanofibers from Polymer Blends, Macromol. Mater. Eng. 291
(2006) 1307-1314.
[41] A. Hglund, M. Hakkarainen, A.-C. Albertsson, Degradation Profile of
Poly(ε-caprolactone)-the Influence of Macroscopic and Macromolecular
Biomaterial Design, J. Macromolecular Sci. Part A, 44 (2007) 1041-
1046.
[42] A.R. Tzafriri, Mathematical modeling of diffusion-mediated release from
bulk degrading matrices, J Con Rel 63 (2000) 69-79.
[43] M. Miyajima, A. Koshika, J. Okada, M. Ikeda, K. Nishimura, Effect
of polymer crystallinity on papaverine release from poly(L-lactic acid)
matrix, Journal of Controlled Release 49 (1997) 207-215
29
